Advertisement
News
Advertisement

Abviva Announces Notice of Canadian Patent for Technology Used in Breast Cancer Diagnostics and Therapeutics

Mon, 07/26/2010 - 8:32am
Bio-Medicine.Org

SANTA BARBARA, Calif., July 26 /PRNewswire-FirstCall/ -- Abviva, Inc. (Pink Sheets: ABVV), a biomedical company engaged in the development and commercialization of breast cancer-related applications of Mammastatin, announced that the Canadian Patent Office issued notice that it will be issuing patent application Number 2.267.095 within 12 weeks.

The Mammastatin technology continues to increase its protection as evidenced by the granting of patents around its core technology.  In recent months, the Japanese Patent Office issued two patents on the Mammastatin technology, and the Canadian patent will help protect the technology when it begins international expansion.

"The Company is very pleased with this notice of patent to be granted and believes that the issuance of the many patents will allow Abviva to expand internationally in years to come," said Barrett Evans, Abviva's CEO.

About Abviva

Abviva, Inc. is a biomedical company engaged in the innovation, development and commercialization of breast cancer-related applications of Mammastatin, a growth inhibitory protein discovered at the University of Michigan Cancer Center that demonstrated anti-breast cancer properties. The discovery was developed into a simple breast cancer diagnostic blood test that demonstrated healthy women have high or normal levels of the protein and women with breast cancer have no detectable or very low levels of the protein. Abviva intends to commercialize the Mammastatin Serum Assay as a reference test through its wholly owned subsidiary laboratory under CLIA certification.

Statements in this press release that are not strictly historical facts are "forward-looking" statements (iden

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading